10
Articles Count
38910
Viewing Count
Shi Yingzi

PharmaDJ reporter.

China’s May fundraising indicates interest in ear...
Shi Yingzi · 14 days ago
Chinese investors showed more support for young startups in May 2022 as four of them raised over RMB100 million each in early financing rounds, while late-stage drugmakers found fundraising more challenging than ever. Financing activity in May was also the weakest this year, with the least deals and lowest amount.
Further information
China Biotech Fundraising Tracker
Pediatric drug development a new investment area i...
Shi Yingzi · 1 months ago
A drugmaker specializing in medicines for children raising nearly $15.7 million in April 2022 shows a shifting interest toward this area. Early-stage biotech companies also made up 18 of the 27 financing deals.
Further information
China Biotech Fundraising Tracker
RNA therapies making a comeback in March as China ...
Shi Yingzi · 2 months ago
As China battles its worst COVID outbreak, investors have turned their attentions to RNA-based therapies again. But this time, companies are flogging their platform technologies rather than specific programs.
Further information
China Biotech Fundraising Tracker
Chinese investors’ interest in cell and gene ther...
Shi Yingzi · 3 months ago
Cell therapy and gene therapy companies extended a trend from the second half of 2021 by making up 11 of the 21 financing deals in February. PharmaDJ expects this trend to continue throughout the year.
Further information
China Biotech Fundraising Tracker
Cell and gene therapies are making gradual gains w...
Shi Yingzi · 4 months ago
Chinese investors continued to show an interest in innovative drugmakers in the New Year with 41 closing a financing round in January. Companies developing cell and gene therapies were at the forefront, receiving 29% of all disclosed funding.
Further information
China Biotech Fundraising Tracker
Massive series A rounds in December 2021 highlight...
Shi Yingzi · 5 months ago
Several big series A financing in December warrant attention, as they speak of a wider trend for drug innovation in China. Big pharmaceutical companies are sharing risks, and scientists are creating a mRNA platform.
Further information
China Biotech Fundraising Tracker
mRNA and CNS mark November biotech fundraising in ...
Shi Yingzi · 6 months ago
Chinese drugmakers raised $1.26 billion in 28 financing rounds in November, representing the third highest amount of funds raised this year. This was mainly attributed to mRNA vaccine maker Abogen Biosciences’ $300 million series C+ round and CNS specialist Ignis Therapeutics’ $180 million series A round.
Further information
China Biotech Fundraising Tracker
COVID-19 vaccine makers lose luster in October
Shi Yingzi · 7 months ago
As vaccination rates continue to rise and therapeutic drugs for COVID-19 are coming to the market, vaccine makers are taking a hit, as reflected by their lackluster financing performance in October.
Further information
China Biotech Fundraising Tracker
Do NMPA Approvals Cause Share Prices to Rise?
Shi Yingzi · 11 months ago
three fourths of stocks to rise on the day of approval.
Further information
Feature
China Approved its First Cell Therapy
Shi Yingzi · 11 months ago
On June 22, NMPA green-lighted Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B cell lymphoma.
Further information
News

Personal Information

Email:

shi.yingzi@pharmadj.com

Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement